Current developments in the therapy of protozoan infections

Open Medicinal Chemistry Journal

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 4-10

  Zucca, Mario ^a   Savoia, Dianella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Nanovectors; Protease; Protozoa; Rnai; Topoisomerase

Indexed keywords

AMPHOTERICIN B; AZADIPEPTIDE NITRILE; CAMPTOTHECIN; CECROPIN; CELL PENETRATING PEPTIDE; CRUZIPAIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; FALCIPAIN 2; FALCIPAIN 3; GLUCAN; IRINOTECAN; ITRACONAZOLE; LIPOSOME; MAGAININ DERIVATIVE; NANOCARRIER; NIOSOME; PLASMEPSIN INHIBITOR; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE INHIBITOR; QUERCETIN; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; AMEBIASIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APOPTOSIS; COMPUTER AIDED DESIGN; CRYPTOSPORIDIOSIS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG TARGETING; GENE EXPRESSION; HOST PATHOGEN INTERACTION; HUMAN; LEISHMANIA; LEISHMANIASIS; MALARIA; MICROEMULSION; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RNA INTERFERENCE; TOXOPLASMOSIS; TRYPANOSOMA; VISCERAL LEISHMANIASIS;

EID: 80055088345     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501105010004     Document Type: Review

References (79)

1. Pink, R.; Hudson, A.; Mouries, A.M.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov., 2005, 4, 727-40.
2. Reguera, M.R.; Diaz-Gonzalez, R.; Perez-Pertejo, Y.; Balana- Fouce, R. Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids. Curr. Drug Targets, 2008, 9, 966-78.
3. Dube, A.; Gupta, R.; Singh, N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol., 2009, 25, 432-9.
4. McKerrow, H.J.; Doyle, S.P.; Engel, C.J.; Podust, M.L.; Robertson, A.S.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, D.I.; Brinen, S.L.; Craik, S.C. Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz, 2009, 104, 263-9.
5. Kasam, V.; Zimmermann, M.; Maass, A.; Schwichtenberg, H.; Wolf, A.; Jacq, N.; Breton, V.; Hofmann-Apitius, M. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. J. Chem. Inf. Model, 2007, 47, 1818-28.
6. Jana, S.; Paliwal, J. Novel molecular targets for antimalarial chemotherapy. Int. J. Antimicrob. Agents, 2007, 30, 4-10.
7. Loser, R.; Gutschow, M. Dipeptide-derived nitriles containing additional electrophilic sites: potentially irreversible inhibitors of cysteine proteases. J. Enzyme Inhib. Med. Chem., 2009, 24, 1245-52.
8. Rosenthal, P.J.; Sijwali, P.S.; Singh, A.; Shenai, B.R. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des., 2002, 8, 1659-72.
9. Fah, C.; Hardegger, A.L.; Baitsch, L.; Schweizer, B.W.; Meyer, S.; Bur, D.; Diederich, F. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates. Org. Biomol. Chem., 2009, 7, 3947-57.
10. Hof, F.; Schutz, A.; Fah, C.; Meyer, S.; Bur, D.; Liu, J.; Goldberg, E.D.; Diederich, F. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. Angew. Chem. Int. Ed. Engl., 2006, 45, 2138-41.
11. Liu, K.; Shi, H.; Xiao, H.; Chong, G.A.; Bi, X.; Chang, T.Y.; Tan, S.K.; Yada, Y.R.; Yao, Q.S. Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites. Angew. Chem. Int. Ed. Engl., 2009, 48, 8293-7.
12. Friedman, R.; Caflisch, A. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem, 2009, 4, 1317-26.
13. Luksch, T.; Blum, A.; Klee, N.; Diederich, E.W.; Sotriffer, A.C.; Klebe, G. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. ChemMedChem, 2010, 5, 443-54.
14. Duschak, G.V.; Couto, S.A. Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Curr. Med. Chem., 2009, 16, 3174-202.
15. Vicik, R.; Hoerr, V.; Glaser, M.; Schultheis, M.; Hansell, E.; McKerrow, H.J.; Holzgrabe, U.; Caffrey, R.C.; Ponte-Sucre, A.; Moll, H.; Stich, A.; Schirmeister, T. Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg. Med. Chem. Lett., 2006, 16, 2753-7.
16. Buback, V.; Mladenovic, M.; Engels, B.; Schirmeister, T. Rational design of improved aziridine-based inhibitors of cysteine proteases. J. Phys. Chem. B., 2009, 113, 5282-9.
17. Ponte-Sucre, A.; Vicik, R.; Schultheis, M.; Schirmeister, T.; Moll, H. Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob. Agents. Chemother., 2006, 50, 2439-47.
18. Ganguly, A.; Das, B.B.; Sen, N.; Roy, A.; Dasgupta, B.S.; Majumder, K.H. 'LeishMan' topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovani. Nucleic Acids Res., 2006, 34, 6286-97.
19. Deterding, A.; Dungey, A.F.; Thompson, A.K.; Steverding, D. Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop., 2005, 93, 311-6.
20. Marquis, F.J.; Makhey, D.; LaVoie, J.E.; Olivier, M. Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection. J. Parasitol., 2003, 89, 1048-52.
21. Proulx, E.M.; Desormeaux, A.; Marquis, F.J.; Olivier, M.; Bergeron, G.M. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob. Agents Chemother., 2001, 45, 2623-7.
22. Sen, N.; Das, B.B.; Ganguly, A.; Mukherjee, T.; Tripathi, G.; Bandyopadhyay, S.; Rakshit, S.; Sen, T.; Majumder, K.H. Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ., 2004, 11, 924-36.
23. Sithiprom, S.; Petmitr, S.; Chavalitshewinkoon-Petmitr, P. Partial purification and characterization of Trichomonas vaginalis DNA topoisomerase II. Southeast Asian J. Trop. Med. Public Health, 2009, 40, 877-85.
24. Hancock, R.E.; Scott, M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA, 2000, 97, 8856-61.
25. Steinstraesser, L.; Kraneburg, U.M.; Hirsch, T.; Kesting, M.; Steinau, H.U.; Jacobsen, F.; Al-Benna, S. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci., 2009, 10, 3951-70.
26. Bommarius, B.; Kalman, D. Antimicrobial and host defense peptides for therapeutic use against multidrug-resistant pathogens: new hope on the horizon. IDrugs, 2009, 12, 376-80.
27. Mor, A. Multifunctional host defense peptides: antiparasitic activities. FEBS J., 2009, 276, 6474-82.
28. Hancock, R.E.; Rozek, A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol. Lett., 2002, 206, 143-9.
29. Oren, Z.; Shai, Y. Mode of action of linear amphipathic alphahelical antimicrobial peptides. Biopolymers, 1998, 47, 451-63.
30. Hwang, P.M.; Vogel, H.J. Structure-function relationships of antimicrobial peptides. Biochem. Cell. Biol., 1998, 76, 235-46.
31. Rivas, L.; Luque-Ortega, R.J.; Andreu, D. Amphibian antimicrobial peptides and Protozoa: lessons from parasites. Biochim. Biophys. Acta, 2009, 1788, 1570-81.
32. Savoia, D.; Guerrini, R.; Marzola, E.; Salvadori, S. Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorg. Med. Chem., 2008, 16, 8205-9.
33. Luque-Ortega, R.J.; van't Hof, W.; Veerman, C.E.; Saugar, M.J.; Rivas, L. Human antimicrobial peptide histatin 5 is a cellpenetrating peptide targeting mitochondrial ATP synthesis in Leishmania. FASEB J., 2008, 22, 1817-28.
34. Sharma, K.R.; Reddy, P.R.; Tegge, W.; Jain, R. Discovery of Trp- His and His-Arg analogues as new structural classes of short antimicrobial peptides. J. Med. Chem., 2009, 52, 7421-31.
35. Rodziewicz-Motowidlo, S.; Mickiewicz, B.; Greber, K.; Sikorska, E.; Szultka, L.; Kamysz, E.; Kamysz, W. Antimicrobial and conformational studies of the active and inactive analogues of the protegrin-1 peptide. FEBS J., 2010, 277, 1010-22.
36. Saviello, R.M.; Malfi, S.; Campiglia, P.; Cavalli, A.; Grieco, P.; Novellino, E.; Carotenuto, A. New insight into the mechanism of action of the temporin antimicrobial peptides. Biochemistry, 2010, 49, 1477-85.
37. Prudencio, M.; Lehmann, J.M. Illuminating the host - how RNAi screens shed light on host-pathogen interactions. Biotechnol. J., 2009, 4, 826-37.
38. Tyc, J.; Faktorova, D.; Kriegova, E.; Jirku, M.; Vavrova, Z.; Maslov, A.D.; Lukes, J. Probing for primary functions of prohibitin in Trypanosoma brucei. Int. J. Parasitol., 2010, 40, 73-83.
39. Price, P.H.; Guther, L.M.; Ferguson, A.M.; Smith, F.D. Myristoyl- CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol. Biochem. Parasitol., 2010, 169, 55-8.
40. Caceres, J.A.; Michels, A.P.; Hannaert, V. Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. Mol. Biochem. Parasitol., 2010, 169, 50-4.
41. Monnerat, S.; Clucas, C.; Brown, E.; Mottram, C.J.; Hammarton, C.T. Searching for novel cell cycle regulators in Trypanosoma brucei with an RNA interference screen. BMC Res. Notes, 2009, 2, 46.
42. Vinet, F.A.; Fukuda, M.; Turco, J.S.; Descoteaux, A. The Leishmania donovani lipophosphoglycan excludes the vesicular proton- ATPase from phagosomes by impairing the recruitment of synaptotagmin V. PLoS Pathog., 2009, 5, e1000628.
43. Blandin, A.S.; Wang-Sattler, R.; Lamacchia, M.; Gagneur, J.; Lycett, G.; Ning, Y.; Levashina, A.E.; Steinmetz, M.L. Dissecting the genetic basis of resistance to malaria parasites in Anopheles gambiae. Science, 2009, 326, 147-50.
44. Ngo H.; Tschudi C.; Gull K.; Ullu E. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc. Natl. Acad. Sci. U S A, 1998, 95, 14687-92.
45. Wang, Z.; Morris, C.J.; Drew, E.M.; Englund, T.P. Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J. Biol. Chem., 2000, 275, 40174-9.
46. Claser, C.; Curcio, M.; de Mello, M.S.; Silveira, V.E.; Monteiro P.H.; Rodrigues M.M. Silencing cytokeratin 18 gene inhibits intracellular replication of Trypanosoma cruzi in HeLa cells but not binding and invasion of trypanosomes. BMC Cell Biol., 2008, 9, 68.
47. Aouadi, M.; Tesz, J.G.; Nicoloro, M.S.; Wang, M.; Chouinard, M.; Soto, E.; Ostroff, R.G.; Czech, P.M. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature, 2009, 458, 1180-4.
48. Crombez, L.; Aldrian-Herrada, G.; Konate, K.; Nguyen, N.Q.; McMaster, K.G.; Brasseur, R.; Heitz, F.; Divita, G. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther., 2009, 17, 95-103.
49. Frankel, D.A.; Pabo, O.C., Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55, 1189-93.
50. Green, M.; Loewenstein, M.P. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell, 1988, 55, 1179-88.
51. Endoh, T.; Ohtsuki, T. Cellular siRNA delivery using cellpenetrating peptides modified for endosomal escape. Adv. Drug. Deliv. Rev., 2009, 61, 704-9.
52. Heitz, F.; Morris, C.M.; Divita, G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol., 2009, 157, 195-206.
53. Nekhotiaeva, N.; Elmquist, A.; Rajarao, K.G.; Hallbrink, M.; Langel, U.; Good, L. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J., 2004, 18, 394-6.
54. Arrighi, B.R.; Ebikeme, C.; Jiang, Y.; Ranford-Cartwright, L.; Barrett, P.M.; Langel, U.; Faye, I. Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falcipa rum and Trypanosoma brucei brucei. Antimicrob. Agents Chemother., 2008, 52, 3414-7.
55. Prieto, H.J.; Koncarevic, S.; Park, K.S.; Yates, J. 3rd; Becker, K. Large-scale differential proteome analysis in Plasmodium falciparum under drug treatment. PLoS One, 2008, 3, e4098.
56. Pays, E.; Vanhollebeke, B. Mutual self-defence: the trypanolytic factor story. Microbes Infect., 2008, 10, 985-9.
57. Baral, T.N.; Magez, S.; Stijlemans, B.; Conrath, K.; Vanhollebeke, B.; Pays, E.; Muyldermans, S.; De Baetselier, P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Med. Sci., 2006, 12, 580-4.
58. El Fadili, K.; Drummelsmith, J.; Roy, G.; Jardim, A.; Ouellette, M. Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Exp. Parasitol., 2009, 123, 51-7.
59. Kayser, O.; Kiderlen, F.A., Delivery strategies for antiparasitics. Expert Opin. Investig. Drugs, 2003, 12, 197-207.
60. Ordonez-Gutierrez, L.; Espada-Fernandez, R.; Dea-Ayuela, A.M.; Torrado, J.J.; Bolas-Fernandez, F.; Alunda, M.J. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int. J. Antimicrob. Agents, 2007, 30, 325-9.
61. Torrado, J.J.; Espada, R.; Ballesteros, P.M.; Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci., 2008, 97, 2405-25.
62. Santos-Magalhaes, S.N.; Mosqueira, C.V. Nanotechnology applied to the treatment of malaria. Adv. Drug. Deliv. Rev., 2010, 62, 560-575.
63. Basu, K.M.; Lala, S. Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med., 2004, 4, 681-9.
64. Lala, S.; Gupta, S.; Sahu, N.P.; Mandal, D.; Mondal, N.B.; Moulik, S.P.; Basu, M.K. Critical evaluation of the therapeutic potential of basic acid incorporated in oil-in-water microemulsions and poly- D,L-lactide nanoparticles against experimental leishmaniasis. J. Drug Target., 2006, 14, 171-9.
65. Medda, S.; Jaisankar, P.; Manna, R.K.; Pal, B.; Giri, V.S.; Basu, M.K. Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J. Drug Target., 2003, 11, 123-8.
66. Sarkar, S.; Mandal, S.; Sinha, J.; Mukhopadhyay, S.; Das, N.; Basu, M.K. Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J. Drug Target., 2002, 10, 573-8.
67. Sanchez-Brunete, A.J.; Dea, A.M.; Rama, S.; Bolas, F.; Alunda, M.J.; Torrado-Santiago, S.; Torrado, J.J. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J. Drug Target., 2005, 13, 225-33.
68. Manzano, M.; Colilla, M.; Vallet-Regi, M. Drug delivery from ordered mesoporous matrices. Expert Opin. Drug Deliv., 2009, 6, 1383-400.
69. Van Speybroeck, M.; Barillaro, V.; Thi, D.T.; Mellaerts, R.; Martens, J.; Van Humbeeck, J.; Vermant, J.; Annaert, P.; Van den Mooter, G.; Augustijns, P. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J. Pharm. Sci., 2009, 98, 2648-58.
70. Mellaerts, R.; Mols, R.; Jammaer, A.J.; Aerts, A.C.; Annaert, P.; Van Humbeeck, J.; Van den Mooter, G.; Augustijns, P.; Martens, A.J. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm., 2008, 69, 223-30.
71. Leroy, D.; Doerig, C. Drugging the Plasmodium kinome: the benefits of academia-industry synergy. Trends Pharmacol. Sci., 2008, 29, 241-9.
72. Croft, L.S. Kinetoplastida: new therapeutic strategies. Parasite, 2008, 15, 522-7.
73. Wolf, A.; Shahid, M.; Kasam, V.; Ziegler, W.; Hofmann-Apitius, M. In Silico Drug Discovery Approaches on Grid Computing Infrastructures. Curr. Clin. Pharmacol., 2010, 5, 37-46
74. Kasam, V.; Salzemann, J.; Botha, M.; Dacosta, A.; Degliesposti, G.; Isea, R.; Kim, D.; Maass, A.; Kenyon, C.; Rastelli, G.; Hofmann-Apitius, M.; Breton, V. WISDOM-II: screening against multiple targets implicated in malaria using computational grid infrastructures. Malar. J., 2009, 8, 88.
75. Chavain, N.; Davioud-Charvet, E.; Trivelli, X.; Mbeki, L.; Rottmann, M.; Brun, R.; Biot, C. Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg. Med. Chem., 2009, 17, 8048-59.
76. Ribeiro, R.R.; Ferreira, A.W.; Martins, S.P.; Neto, L.R.; Rocha, G.O.; Le Moyec, L.; Demicheli, C.; Frezard, F. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta-cyclodextrin conjugates. Biopharm. Drug Dispos., 2010, 31, 109-119.
77. Ribeiro, R.R.; Moura, P.E.; Pimentel, M.V.; Sampaio, M.W.; Silva, M.S.; Schettini, A.D.; Alves, F.C.; Melo, A.F.; Tafuri, L.W.; Demicheli, C.; Melo, N.M.; Frezard, F.; Michalick, S.M. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob. Agents Chemother., 2008, 52, 2564-72.
78. Kraus, M.J.; Verlinde, L.C.; Karimi, M.; Lepesheva, I.G.; Gelb, H.M.; Buckner, S.F. Rational modification of a candidate cancer drug for use against Chagas disease. J. Med. Chem., 2009, 52, 1639-47.
79. Sutherland, J.C. Comparing highly efficacious antimalarial drugs. PLoS Med., 2008, 5, e228.